ID   ES8-SLFN11-KO
AC   CVCL_C6N6
DR   Wikidata; Q116048948
RX   PubMed=34413129;
CC   Population: Caucasian.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 26633; SLFN11.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (from parent cell line).
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1204 ! ES8
SX   Male
AG   10Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 21-03-23; Version: 2
//
RX   PubMed=34413129; DOI=10.1158/1535-7163.MCT-21-0089;
RA   Gartrell J., Mellado-Largarde M., Clay M.R., Bahrami A., Sahr N.A.,
RA   Sykes A., Blankenship K., Hoffmann L., Xie J., Cho H.P., Twarog N.,
RA   Connelly M., Yan K.-K., Yu J.-Y., Porter S.N., Pruett-Miller S.M.,
RA   Neale G., Tinkle C.L., Federico S.M., Stewart E.A., Shelat A.A.;
RT   "SLFN11 is widely expressed in pediatric sarcoma and induces variable
RT   sensitization to replicative stress caused by DNA-damaging agents.";
RL   Mol. Cancer Ther. 20:2151-2165(2021).
//